| 期 |
栏目 |
标题 |
文件 |
| 编号 3 (2012) |
Articles |
THE NOVEL HIV NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR RILPIVIRINE: A REVIEW OF INTERNATIONAL CLINICAL TRIALS |
|
| 编号 1 (2013) |
Articles |
USE OF THE FUSION INHIBITOR ENFUVIRTIDE IN ANTIRETROVIRAL THERAPY REGIMENS FOR HIV-INFECTED PATIENTS |
|
| 编号 2 (2013) |
Articles |
THE HEPATITIS C VIRUS PROTEASE INHIBITOR TELAPREVIR IN THERAPY REGIMENS FOR CHRONIC HEPATITIS C IN PATIENTS WITH HIV INFECTION |
|
| 编号 6 (2013) |
Articles |
CONTRIBUTION OF A FIXED-DOSE ABACAVIR/LAMIVUDINE COMBINATION TO IMPROVING TREATMENT COMPLIANCE IN HIV-INFECTED PATIENTS |
|
| 编号 1 (2015) |
Articles |
Hepatotoxicity of antiretroviral therapy in HIV-infected patients |
|
| 编号 1 (2015) |
Articles |
A fixed-dose combination of abacavir/lamivudine as a nucleoside basis for first-line antiretroviral therapy regimens |
|
| 编号 2 (2015) |
Articles |
EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY REGIMENS CONTAINING ETRAVIRINE FOR HIV-INFECTED PATIENTS |
|
| 编号 6 (2015) |
Articles |
HIV drug resistance: Dolutegravir is a second-generation HIV integrase inhibitor |
|
| 编号 2 (2011) |
Articles |
THE HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ABACAVIR AND LAMIVUDINE IN FIRST-LINE ANTIRETROVIRAL THERAPY REGIMENS |
|
| 卷 10, 编号 3 (2020) |
Articles |
THE PROBLEM OF BODY WEIGHT GAIN IN HIV-INFECTED PATIENTS DURING ANTIRETROVIRAL THERAPY |
|
| 卷 10, 编号 4 (2020) |
Articles |
Impact of the organism’s genetic traits on the development of secondary and concomitant diseases in patients with HIV infection |
|
| 卷 11, 编号 3 (2021) |
Articles |
Results of treatment with a 60-week Russian ART regimen in patients with HIV infection |
|
| 卷 11, 编号 4 (2021) |
Articles |
The clinical course of HIV/ COVID-19 co-infection and approaches to its therapy |
|
| 卷 11, 编号 4 (2021) |
Articles |
Randomized, open-label, controlled, comparative study on switching HIV-infected patients with their antiretroviral therapy experience to a DTG and 3TC regimen: 96-weeks results |
|
| 卷 12, 编号 3 (2022) |
Articles |
Comparative analysis of clinical and laboratory outcomes in HIV-infected patients vaccinated and not vaccinated against COVID-19 |
|
| 卷 12, 编号 3 (2022) |
Articles |
The efficiency and safety of ART after switching patients to the combined Russian NRTI phosphaladine in combination with elsulfavirine |
|
